Research programme: SCD-1 inhibitors - Glenmark Pharmaceuticals Ltd
Alternative Names: GRC 9332Latest Information Update: 16 Jul 2016
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class
- Mechanism of Action Stearoyl-CoA desaturase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Lipid metabolism disorders; Metabolic disorders; Obesity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lipid-metabolism-disorders in India
- 16 Jul 2016 No recent reports of development identified for preclinical development in Metabolic-disorders in India
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in India